Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Heatmap
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
LYEL
#2840
Lyell Immunopharma, Inc. Common Stock
24.460
0
USD
-1.37%
Setor:
Cuidados de saúde
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
-1.37%
Mudança mensal
+14.46%
Mudança em 6 meses
+1.12%
Mudança anual
+1.12%
Fechamento anterior
24.800
0
Abrir
24.370
0
Bid
Ask
Mínimo
24.360
0
High
24.500
0
Volume
14
Mercados
Ações
Cuidados de saúde
LYEL
Abrir gráfico completo
Financials
Visão geral
Relatórios
Estatísticas
Trimestral
Ano
Valor
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
12.27 M
12.48 M
12.7 M
14.76 M
23.31 M
—
Valuation ratios
Enterprise value
1.61 B
715.13 M
390.5 M
83.35 M
657.21 M
987.81 M
Price to earnings ratio
-4.21
-4.54
-2.27
-0.49
-1.92
-3.42
Price to sales ratio
0.1
9.8
4 073.65
2 743.4
14.61 K
24.8 K
Price to cash flow ratio
-0.01
-4.9
-3.24
-1.03
-3.51
-6.49
Price to book ratio
0
1
0.81
0.44
2.12
2.46
Enterprise value to EBITDA ratio
-7.98
-4.23
-1.72
-0.25
-2.55
-3.54
Profitability ratios
Return on assets %
-0.22
-0.2
-0.31
-0.7
-0.81
-0.74
Return on equity %
-0.27
-0.22
-0.36
-0.9
-1.11
-0.98
Return on invested capital %
-127.37
-129.16
-275.12
-562.33
-869.26
—
Gross margin %
100
100
100
100
100
400
Operating margin %
-2 016.68
-220.89
-190.01 K
-588.12 K
-748.34 K
-3.78 M
EBITDA margin %
-1 888.75
-199.61
-174.43 K
-555.94 K
-716.29 K
-3.64 M
Net margin %
-2 349.47
-216.24
-180.49 K
-562.29 K
-762.36 K
-3.88 M
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
13.4
17.59
16.07
7.06
5.28
30.71
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.08
0
0
0
0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-18.58 K
-13.72
-13.04
-12.42
-8.78
-9.49
EBIT per share
-31.6 K
-15.14
-19.68
-27.44
-15.76
-16.58
EBITDA per share
-29.6 K
-13.68
-18.07
-25.94
-15.09
-15.86
Total debt per share
—
—
—
—
—
—
Cash per share
90.62 K
51.82
43.53
28.34
14.46
71.08
Net current asset value per share
92.16 K
52.72
44.2
29.03
15.27
73.26
Tangible book value per share
136.82 K
67.45
52.19
29.28
14.52
75.55
Working capital per share
85.28 K
49.72
41.45
24.92
12.38
63.34
Book value per share
136.82 K
67.45
52.19
29.28
14.52
75.55
Notícias
Lyell Immunopharma Stock (LYEL) Slides Despite Praise from a Top Wall Street Analyst - TipRanks.com
Morning News Wrap-Up 4/10/26: Today’s Biggest Stock Market Stories! - TipRanks.com
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL)
H.C. Wainwright reitera classificação de compra para ações da Lyell Immunopharma
Citizens reitera classificação das ações da Lyell Immunopharma com base no progresso dos ensaios
Citizens reiterates Lyell Immunopharma stock rating on trial progress
Avago, Lumentum among market cap stock movers on Monday
Lyell Immunopharma conclui tranche de US$ 50 milhões e nomeia novo CFO
Lyell Immunopharma closes $50M equity tranche, names new CFO
Citizens inicia cobertura da Lyell Immunopharma com classificação outperform e preço-alvo de US$ 34
Citizens initiates Lyell Immunopharma stock at outperform, $34 target
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript